NDRA is a smaller portion of my long term bagNDRA with it's consistent dilution has been a little rough.
Had a small position go 88% down and that was my cue to toss more in to fix the average price.
I do believe the clinical trials pass with great results and this will be used complementary to MRI and other tech/procedures that are currently done and more that will be created into the future.
NOT FINANCIAL ADVICE
NDRA trade ideas
NDRA larger timeframe look and highest targetWhat will hyperinflation cause??
Someday good news will come and be good news for this one but i would guess it could be near 2028 we would see a price above $200 if the world governments really bend the knee to the cabal... We are currently on the course for this happening BUT a quick deflationary time should happen first to shake all out.
This is not financial advice I'm not going to make you rich with these wild ideas but if it goes up to $2 and down to 0.2 before making they run and you time it correctly you will be selling into the market makers as they are pumping it up and possibly creating generational wealth or like in Venezuela you'd have enough money to get a cheese burger at McDonalds......
NDRA mega pump incoming & VHAI I also is about to blow up!!The final wave down isn't going to start til we pump back upto $1.50 or higher.
We have completed wave 1 & 3 of this wave and are in the B wave that I believe will get us above .60 before dumping to take the low.
After taking the low I assume we will then fill the gap.
Should have some serious volitility. At any poing they get enough shorts in I believe they will take $1.50 gap out but they need to trick enough into it.
With the perfect conditions and a big enough liquidation event I see $3.2 -$4 also targets before starting the wave 5 down.
I believe we can see an total beat down when/ very soon after they announce 0.50 rate cuts and that should suppress many small & micro caps til March
$NDRA OVERSOLD 4HR RSI & DOUBLE BOTTOM **NDRA Life Sciences (NDRA): A High-Potential Opportunity for Massive Gains! **
**Based on the recent earnings call and updates, NDRA Life Sciences is shaping up as a tremendous opportunity with extraordinary upside potential.** Currently trading at a mere $0.42 per share, this stock has plummeted a shocking 90% in the past three weeks, largely driven by a 1-for-50 reverse stock split and an $8 million public offering. This sharp decline, fueled by panic and fear, has created a golden opportunity for those ready to buy the dip and capitalize on a potential breakout and bullish reversal. With a market cap of just $550,000, the potential for explosive gains is undeniable.
**Why NDRA is a Must-Watch:**
- **Strong Financial Backing:** NDRA is fully funded until mid-2025, providing the financial security needed to advance its groundbreaking TAEUS® technology, which could revolutionize liver fat measurement and address a critical global health issue. This technology targets over 1 billion people suffering from conditions like NAFLD and NASH, potentially transforming how liver diseases are diagnosed and treated.
- **Bullish Technical Signals:**
- NDRA is flashing strong bullish signals, primed for a breakout and bullish reversal. The stock is deeply oversold on the RSI, a classic indicator for a sharp rebound. There's also a hidden bullish divergence, suggesting underlying strength as the RSI makes higher lows while the price drops. The stock price has recently moved above the VWAP, signaling increased buying interest and momentum.
- NDRA has been granted an extension until November 20, 2024, to regain NASDAQ compliance, which involves maintaining a $1.00 bid price for 10 consecutive trading days. The pressure to achieve this could trigger a powerful surge, especially given the potential for a short squeeze.
- **Potential for Big Moves Ahead:**
- The possibility of insider buying, a buyout, partnership, or merger isn't off the table, adding even more fuel to the fire. Social media influencers are starting to take notice and invest, which could further amplify the momentum.
- **Unmatched Growth Potential:**
- Recent reports show NDRA's cash position has more than doubled to $6.4 million, with a significant reduction in operating expenses. These solid fundamentals underpin a strong runway for growth and innovation.
- **Price Targets and Speculative Gains:**
- Given the current setup, NDRA has the potential to reach $1.00, $2.00, or even $5.00 in the near term. The stock's ability to gain compliance and its strategic financial positioning make it a compelling opportunity for investors looking for high-risk, high-reward plays.
**Don't miss out on this opportunity.** Buy the panic and fear. If you sold NDRA during the recent drop, you might regret it as the stock rebounds and potentially soars. Always do your research before making any investment decisions, but remember that timing is everything in these volatile markets!
*Note: This is not financial advice. Always do your own research before making any investment decisions.*
---
Harmonic Cypher Final Data from Robarts study coming September, in Spain. To learn more about TAEUS, click here .
Company ran by ex-GE executives. TAM is in the Billions of Dollars $$. Low float.
Recently broke long-term down trend. Daily, Weekly, Monthly charts #BULLISH. Fibonacci convergence at 618 fib (projection) into September time frame.
Follow me on twitter and instagram @ #VolatilityWatch
Disclaimer: I am long NDRA. This is not a recommendation to buy or sell. Please do your homework before investing.
Deja Vu?Almost exactly one-year ago NDRA received this same form 8-K "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing." *Shortly after recieving this notice, NDRA's Price shot up dramatically.
In September, ENDRA Life Sciences is planning to present the final results of the #Robarts study in conjunction with the upcoming EASL-NAFLD Summit in Seville, Spain.
Pattern is very similar to last year's notification.
Disclosure: I am long NDRA. This is not a note to buy or sell. Please do your own Homework before investing.